GLPwatch
Parkinson's disease
Investigational / off-label
Last updated 2026-05-28 15:46 UTCMultiple preclinical studies and clinical trials suggest that GLP-1 receptor agonists, including exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide, show neuroprotective effects in models of Parkinson's disease, with some trials (e.g., exenatide and lixisenatide) reporting sustained motor and cognitive benefits in patients.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for parkinson's disease in our data. Any research below reflects investigational or off-label study.
Research (50)
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Exenatide and the treatment of patients with Parkinson's disease.
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
- Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
- Trial of Lixisenatide in Early Parkinson's Disease.
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
- The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
- Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
- Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
- The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
- Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
- A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
- Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis.
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
- Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Neuroprotective effects of liraglutide for stroke model of rats.
- Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection.
- Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
- Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.
- Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
- Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain.
- Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.
- Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
- A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
- Insulin resistance and exendin-4 treatment for multiple system atrophy.
- Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
Common questions
- Which GLP-1 drugs are FDA-approved for Parkinson's disease?
- No GLP-1 drug is currently FDA-approved for parkinson's disease; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Parkinson's disease?
- GLPwatch tracks 127 research papers on GLP-1 drugs and parkinson's disease. This research is investigational and does not imply FDA approval.